GGrantIndex
← Leaderboards

Matthew Edward Burow

Tulane University Of Louisiana

$4,380,869
Attributed
$6,397,331
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $939.5K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,397,331 · 4

By mechanism

R01$6,230,581 · 3
R03$166,750 · 1

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsPhosphotransferasesPathway InteractionsSignal TransductionSignal PathwayBiologicalLinkPlayCellsDrug DevelopmentMolecularResponseProteinsResearch PersonnelDesignGene ExpressionPhysiologicalInsightProgramsProtein KinaseCell LinePharmaceutical PreparationsCommunitiesMigration

Grant awards (20)

Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$626,742
R01 · FY2025 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$595,679
R01 · FY2024 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$174,596
R01 · FY2024 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$169,251
R01 · FY2024 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$614,579
R01 · FY2023 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer (Diversity Supplement - Belgodere)$110,183
R01 · FY2023 · CA
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer$636,146
R01 · FY2022 · CA
Characterization of an understudied kinase, NEK5, in acquisition of a mesenchymaland migratory cell phenotype$166,750
R03 · FY2020 · TR · contact PI
MEK5-Erk5 in breast cancer resistance$291,987
R01 · FY2014 · CA · contact PI
MEK5-Erk5 in breast cancer resistance$282,926
R01 · FY2013 · CA · contact PI
MEK5-Erk5 in breast cancer resistance$300,953
R01 · FY2012 · CA · contact PI
MEK5-Erk5 in breast cancer resistance$300,923
R01 · FY2011 · CA · contact PI
MEK5-Erk5 in breast cancer resistance$322,449
R01 · FY2010 · CA · contact PI
P13K/AKT crosstalk with ER-signaling and cell survival$275,977
R01 · FY2008 · DK · contact PI
P13K/AKT crosstalk with ER-signaling and cell survival$281,609
R01 · FY2007 · DK · contact PI
P13K/AKT crosstalk with ER-signaling and cell survival$65,560
R01 · FY2007 · DK · contact PI
P13K/AKT crosstalk with ER-signaling and cell survival$290,021
R01 · FY2006 · DK · contact PI
P13K/AKT crosstalk with ER-signaling and cell survival$297,000
R01 · FY2005 · DK
P13K/AKT crosstalk with ER-signaling and cell survival$297,000
R01 · FY2004 · DK
P13K/AKT crosstalk with ER-signaling and cell survival$297,000
R01 · FY2003 · DK